AIAbdulrahman Ismael

Abdulrahman Ismael

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Abdulrahman Ismael has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Carbon Monoxide at the Toxicology–Therapeutics Interface: Donor Validation, the Endogenous Baseline and Regulatory Separation

    by Syako S. Hasan, Rebaz M. Mustafa, Dlzar D. Ghafoor, Akam Jasim Mustafa, Harmand A. Hama, Nyan Masud, Rayan A. Hussain, Abdulrahman Ismael, Rebaz Qader

    Carbon monoxide (CO) occupies an unusual position at the boundary between environmental toxicology and therapeutic pharmacology. The same molecule is regulated as an involuntary toxic exposure in public‐health and occupational settings, yet it is also being explored as a controlled therapeutic agent in acute inflammation, organ preservation, wound repair and selected local‐delivery indications. This critical narrative review was written to clarify three issues that have repeatedly distorted interpretation of the field: the quantitative endogenous baseline of CO (a haem‐derived pool that can approach roughly 150 μmol/L in blood, far above a trace contaminant), the analytical validity of CO donor systems and the need to keep environmental exposure limits separate from drug‐development risk assessment. Structured scoping searches of PubMed, Web of Science and the Cochrane Library were used to identify mechanistic, toxicological, donor chemistry, exposure metric and regulatory literature through November 2025. We place particular weight on post‐2018 evidence showing that widely used ruthenium carbonyls, especially CORM‐2 and CORM‐3, do not behave as reliable CO donors under many physiological conditions and that several historical biological effects may reflect ruthenium reactivity rather than CO signalling. We argue that CO studies should be read through a donor‐validation filter that favours gaseous CO, physiologically characterised organic donors, gas‐entrapping materials and measured exposure metrics such as carboxyhaemoglobin (COHb). To make this operational, we propose a three‐tier evidence scheme for grading CO biology and a minimum reporting set for CO intervention studies. The most defensible translational opportunities are short, monitored and reversible interventions in acute or localised settings; chronic systemic inhalation for diffuse disease remains less plausible because systemic COHb elevation cannot be confined to the diseased tissue. For applied toxicology, a coherent framework for CO therefore requires validated exposure metrics, explicit donor chemistry and strict separation of therapeutic benefit–risk assessment from population‐protective environmental limits.

  • Open Access

    Centaurea virgata Lam. Instigates EtOH‐Induced Gastric Toxicity/Ulcer In Vivo: Role of SOD/MDA, Bax/HSP 70, and TNF‐α/IL‐10

    by Khalid M. Alqaisi, Essa Qarani Rashid, Abdulrahman Ismael, Hawar Jawdat Jaffar, Ahmed A. J. Jabbar, Gharieb S. El-Sayyad, Hanan Ibrahim Alsharif, Abdulmohsen I. Algefare, Manal A. Alfwuaires, Marwa Yousry A. Mohamed, et al.

    Centaurea virgata is broadly used as a traditional food and medicine across the globe for numerous health purposes. Although the species is reported to have antioxidant and anti‐inflammatory activities, literature data on its gastroprotective effects are scarce. Due to numerous shortcomings of conventional anti‐ulcer drugs, natural products gained renewed interest as a safer alternative. This study aimed to investigate the acute toxicity and gastroprotective effects of the aerial part extracts of Centaurea virgata (APCV) on ethanol‐induced gastric ulcers in Sprague–Dawley rats. Rats were divided into 5 groups: normal control, ulcer control (saline + EtOH), reference (lansoprazole + EtOH), APCV 100 mg/kg + EtOH, and APCV 200 mg/kg + EtOH. APCV 100 or 200 mg/kg, administered orally 1 h before the ethanol‐induced ulcer procedure delivery, increased the protective index % (26.82% and 31.40%, respectively). The histopathological results (using H&E and PAS) indicated preserved gastric defense barriers (restored mucus secretion and gastric pH) and tissue architecture as a result of APCV pretreatment. APCV intervention (100 and 200 mg/kg) increased superoxide dismutase by 24.33% and 62.14%; catalase by 59.07% and 90.37%; and upregulated IL‐10 by 24.40% and 79.52%, while significantly ( p < 0.01) lowering MDA by 25.97% and 38.77%, as well as significantly ( p < 0.001) downregulated IL‐6 by 14.67% and 33.08% and TNF‐α by 37.82% and 47.59%, respectively, compared to ulcer controls. It could also be noted that inhibited apoptosis (inhibited pro‐apoptotic Bax and increased HSP 70 appearances in gastric tissues) occurred in gastric tissues pretreated with APCV. Taken together, APCV exhibited a gastroprotective potential against gastric ulcers, which is attributed to its attenuation effects on oxidative stress, inflammatory, and apoptotic pathways.